Evaluation of the Safety and Performance of a Bioresorbable Nasal Dressing Containing Mometasone Furoate (MF)
NCT ID: NCT07286201
Last Updated: 2025-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
110 participants
INTERVENTIONAL
2026-01-31
2027-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
OCEAN
Application after nasal/sinus surgery
OCEAN
Biodegradable nasal dressing applied after sinus/nasal surgery
Steroid-eluting Sinus Stent
Application after nasal/sinus surgery
Steroid-eluting sinus stent
Applied after sinus/nasal surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OCEAN
Biodegradable nasal dressing applied after sinus/nasal surgery
Steroid-eluting sinus stent
Applied after sinus/nasal surgery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject is scheduled to undergo bilateral endoscopic sinus surgery for Chronic Rhinosinusitus with nasal polyps (CRSwNP) or without nasal polyps (CRSsNP) and is indicated for bilateral complete ethmoidectomy (anterior and posterior ethmoidectomy) at a minimum. Additional sinuses may be operated on at the surgeon's discretion.
3. Subject is willing and able to provide informed consent.
4. Subject is willing and able to comply with the investigational plan requirements.
5. Subjects with a pre-operative Lund-MacKay stage of 6 (≥3 per nostril).
6. Subject with a pre-operative Lund-Mackay stage side-to-side difference ≤ 2.
7. Subject of child-bearing potential is not pregnant and agrees to not become pregnant during the course of the study.
Exclusion Criteria
2. Subject with an underlying systemic disorders known to affect the nose (e.g., Wegener's granulomatosis, sarcoidosis, Churg-Strauss syndrome, or other systemic vasculitides).
3. Subject with any bleeding disorder or use of medication increasing bleeding risk, except low-dose aspirin.
4. Subject with a known or suspected allergy to device components.
5. Subject with known hemophilia.
6. Subject with insulin dependent diabetes.
7. Subject with an oral steroid dependent condition.
8. Subject with glaucoma, ocular hypertension, posterior subcapsular cataracts.
9. Subject with a (previous) diagnosis of Samter's Triad (AERD).
10. Subject that requires nasal ointments or creams at time of device placement.
11. Subject with a neurological, medical, psychiatric condition, or social circumstance that would potentially increase risk, interfere with study participation, or confound interpretation of study data.
12. Subject with plans to (or otherwise anticipate the need to) undergo an ENT procedure within the 90-day study follow-up.
13. Subject participating in another clinical research study (within 30 days prior to screening up to 90 days post-operative).
14. Subject that used any form of biologics within 90 days prior to sinus surgery and during follow-up to day 25.
15. Subject that used any form of corticosteroid within 2 weeks prior to sinus surgery.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NAMSA
OTHER
Polyganics BV
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIP-6
Identifier Type: -
Identifier Source: org_study_id